EGFR and non-small cell lung carcinoma: The genotyping of ctDNA is routinely used in NSCLC at the time of diagnosis to detect oncogenic alterations or during the first or second generation of EGFR tyrosine kinase inhibitor treatment to detect resistance mutations.1